§ 01 Overview
Overview
Once-weekly GLP-1 receptor agonist approved for type 2 diabetes (2014) with demonstrated cardiovascular benefit in the REWIND trial. One of the three major established GLP-1 drugs alongside semaglutide and liraglutide.
FDA-approved September 2014. REWIND (N=9,901) demonstrated CV benefit including primary prevention. AWARD program showed A1C reductions of 0.8–1.6%. Weight loss ~3–5 kg, modest vs. semaglutide.
§ 02 Mechanism
Mechanism of action
Recombinant GLP-1 analog fused to a modified human IgG4-Fc domain via a small peptide linker. The Fc fusion extends half-life to ~5 days, enabling once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and promote satiety.
- 01FDA-approved for T2D with REWIND CVOT showing 12% MACE reduction
- 02Once-weekly pre-filled pen; no reconstitution required
- 03Real-world safety data across millions of patients
- 04REWIND was the first GLP-1 CVOT to include a primary-prevention population
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 0.75 / 1.5 / 3.0 / 4.5 mg pre-filled pen
- BAC Water
- N/A; pre-filled single-dose pen
- Dose Range
- 0.75–4.5 mg weekly
- Starting Dose
- 0.75 mg weekly
- Route
- SubQ
- Timing
- Any day of week, any time of day
- Frequency
- Weekly
- Cycle
- Continuous use
Storage
Refrigerate unused pens. Stable at room temp for up to 14 days.
§ 04 Evidence
Evidence & research
FDA-approved September 2014. REWIND (N=9,901) demonstrated CV benefit including primary prevention. AWARD program showed A1C reductions of 0.8–1.6%. Weight loss ~3–5 kg, modest vs. semaglutide.
FDA Status
FDA-approved (Trulicity BLA 125469, September 2014).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Mounjaro Approved to Reduce Cardiovascular Risk in Type 2 Diabetes - Docwire News
Mounjaro Approved to Reduce Cardiovascular Risk in Type 2 Diabetes Docwire News
Lilly's Mounjaro had an 8% lower heart-event rate than Trulicity - Stock Titan
Lilly's Mounjaro had an 8% lower heart-event rate than Trulicity Stock Titan
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus - Stocktwits
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus Stocktwits
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus - Yahoo Finance
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus Yahoo Finance
Does Trulicity Cause Weight Loss - View 04zehOhpb - scchr.jp
Does Trulicity Cause Weight Loss - View 04zehOhpb scchr.jp
Dulaglutide For Weight Loss: Benefits, Dosage And Side Effects - Forbes
Dulaglutide For Weight Loss: Benefits, Dosage And Side Effects Forbes
Dulaglutide vs. Semaglutide: What’s The Difference? - Forbes
Dulaglutide vs. Semaglutide: What’s The Difference? Forbes
Trulicity vs Ozempic: Differences, Benefits and Which to Choose - PlexusDx
Trulicity vs Ozempic: Differences, Benefits and Which to Choose PlexusDx
§ 07 Sourcing
Sourcing & supply
Regulatory status
FDA-approved
This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea, diarrhea, vomiting
- 02Abdominal pain, decreased appetite
- 03Injection site reactions
Contraindications
- 01Personal / family history of medullary thyroid carcinoma
- 02MEN 2 syndrome
- 03History of pancreatitis
§ 10 Questions
Dulaglutide FAQ
- What is Dulaglutide?
- Once-weekly GLP-1 receptor agonist approved for type 2 diabetes (2014) with demonstrated cardiovascular benefit in the REWIND trial. One of the three major established GLP-1 drugs alongside semaglutide and liraglutide. Recombinant GLP-1 analog fused to a modified human IgG4-Fc domain via a small peptide linker. The Fc fusion extends half-life to ~5 days, enabling once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and promote satiety.
- What is Dulaglutide used for?
- Reported uses include fda-approved for t2d with rewind cvot showing 12% mace reduction, once-weekly pre-filled pen; no reconstitution required, real-world safety data across millions of patients, and rewind was the first glp-1 cvot to include a primary-prevention population. Evidence strength is rated Established — see the evidence section for detail.
- How is Dulaglutide dosed?
- Commonly referenced dosing is 0.75–4.5 mg weekly, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- How do you reconstitute Dulaglutide?
- For Dulaglutide, vials commonly come in 0.75 / 1.5 / 3.0 / 4.5 mg pre-filled pen and a common reconstitution is N/A; pre-filled single-dose pen. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
- What are the side effects of Dulaglutide?
- Commonly reported side effects include nausea, diarrhea, vomiting, abdominal pain, decreased appetite, and injection site reactions. This list is not exhaustive.
- Is Dulaglutide legal?
- This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status. FDA status: FDA-approved (Trulicity BLA 125469, September 2014)..
§ 11 References
Selected references
- 01
REWIND CVOT
PMID: 31189511 (NCT01394952)
- 02
AWARD-1
PMID: 24463454 (NCT01064687)
- 03
FDA Trulicity label
BLA 125469